Supplementary Table 1. Flow cytometric analyses of HLA-DR, CD45, CD3, CD19, CD16, CD33, CD38, CD34 and CD133 expressed by 11 infusates of autologous bone marrow-derived mesenchymal stem cells.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Isotypic  Control | HLA  -DR | CD45 | CD3 | CD19 | CD16 | CD33 | CD38 | CD34 | CD133 |
| Mean (%) | 0.41 | 0.56 | 0.95 | 0.35 | 0.26 | 0.77 | 0.55 | 0.17 | 0.29 | 0.48 |
| Min (%) | 0.04 | 0.00 | 0.03 | 0.02 | 0.02 | 0.15 | 0.00 | 0.01 | 0.06 | 0.07 |
| Max (%) | 0.92 | 2.39 | 2.41 | 2.98 | 1.31 | 2.32 | 1.86 | 0.48 | 1.06 | 1.70 |
| SD (%) | 0.31 | 2.57 | 0.74 | 0.77 | 0.36 | 0.63 | 0.64 | 0.15 | 9.77 | 0.42 |

Supplementary Table 2. Flow cytometric analyses of CD29, CD44, CD73, CD90, CD105 and CD166 expressed by 11 infusates of autologous bone marrow-derived mesenchymal stem cells.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Isotypic  Control | CD29 | CD44 | CD73 | CD90 | CD105 | CD166 |
| Mean (%) | 0.41 | 99.2 | 97.5 | 99.1 | 99.7 | 96.4 | 99.4 |
| Min (%) | 0.04 | 94.0 | 92.1 | 98.2 | 97.8 | 90.4 | 94.2 |
| Max (%) | 0.92 | 100.0 | 99.9 | 99.9 | 100.0 | 99.6 | 100.0 |
| SD (%) | 0.31 | 1.61 | 3.52 | 1.20 | 0.67 | 14.73 | 1.52 |

Supplementary Table 3. Modified Barthel indices of the control group (n = 4) receiving placebos at the 1st, 12th, 16th, 24th, 36th and 60th week upon completion of the study. Data derived from different time points were compared to the baseline values established at the first week of the study.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Study  Duration (Week) | Modified Barthel Indices | | | | *p*  value |
| UPN05 | UPN06 | UPN07 | UPN12 |
| 1st | 0 | 38 | 86 | 56 |  |
| 12th | 0 | 38 | 83 | 56 | 0.20 |
| 16th | 0 | 38 | 88 | 57 | 0.11 |
| 24th | 0 | 38 | 88 | 57 | 0.11 |
| 36th | 0 | 38 | 88 | 62 | 0.13 |
| 60th | 0 | 33 | 91 | - | 0.45 |

Supplementary Table 4. Functional Independence Measure of the control group (n = 4) having placebos at the 1st, 12th, 16th, 24th, 36th and 60th week upon completion of the study. Data derived from different time points were compared to the baseline values established at the first week of the study.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Study  Duration (Week) | Scores of Functional Independence Measure | | | | *p*  value |
| UPN05 | UPN06 | UPN07 | UPN12 |
| 1st | 19 | 77 | 103 | 79 |  |
| 12th | 19 | 77 | 100 | 77 | 0.05 |
| 16th | 19 | 75 | 106 | 79 | 0.41 |
| 24th | 19 | 77 | 107 | 83 | 0.09 |
| 36th | 19 | 79 | 110 | 86 | 0.06 |
| 60th | 19 | 73 | 111 | - | 0.48 |

Supplementary Table 5. Scores of extended Glasgow Outcome Scale of the control group (n = 4) receiving placebos at the 1st, 12th, 16th, 24th, 36th and 60th week upon completion of the study. Data derived from different time points were compared to the baseline values established at the first week of the study.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Study  Duration (Week) | Scores of Extended Glasgow Outcome Scale | | | | *p*  value |
| UPN05 | UPN06 | UPN07 | UPN12 |
| 1st | 3 | 3 | 5 | 5 |  |
| 12th | 3 | 3 | 5 | 5 | 1 |
| 16th | 3 | 3 | 5 | 5 | 1 |
| 24th | 3 | 3 | 5 | 5 | 1 |
| 36th | 3 | 3 | 5 | 5 | 1 |
| 60th | 3 | 3 | 6 | - | 0.21 |